Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt. A further $700 million follows if ITM’s lead drug wins approval and hits sales targets.
Telix is paying mostly in its own stock, which is why the cost lands on shareholders now. It will issue 105.8 million shares, with the balance made up of ITM debt it assumes, transaction costs, and rolled-over management equity. The deal needs approval from Telix shareholders and regulators, and should close by the end of the year.
Telix is Buying the Supply its Own Drugs Depend on:
Radiopharmaceuticals treat cancer by delivering radiation directly to tumours. They only work if the radioactive isotope arrives in time, because the material decays within days. ITM makes lutetium-177, one of the isotopes the field runs on. Telix says it is also the main outside supplier of that isotope to Pluvicto, the Novartis drug competing with what Telix is building. For Telix, isotope supply has mattered as much as trial results, because a delayed shipment ruins a dose that good data cannot rescue.
Telix has been buying its isotopes from outside suppliers, ITM among them, and after this deal it makes them itself. That removes a supplier margin and a scheduling risk. It also puts Telix on the other side of a competitor’s supply, which is the part regulators will examine.
The deal also buys a drug that beat its trial endpoint but has not cleared the FDA. ITM-11 extended progression-free survival to 23.9 months in gastroenteropancreatic neuroendocrine tumours, well beyond the comparator. The only approved radiopharmaceutical rival is Novartis’s Lutathera. The $700 million in milestones splits between approval and later sales, so Telix pays the bulk upfront and the rest only if the medicine gets through.
Paying in Stock Dilutes Holders Before Any of it Pays Off:
The 105.8 million new shares are the immediate cost. A buyer with pricing power waits for a resubmission before paying, and Telix did not. The stock fell about 10% in New York on the announcement, and more than that in Sydney, before recovering some ground the next day.
Two approvals still stand between announcement and close, one from shareholders and one from regulators. A stock-funded deal asks holders to accept dilution, so the vote is not a formality. Owning the main outside supplier of a competitor’s isotope is the kind of arrangement regulators look at closely.
Then there is ITM-11 itself, and this is not hypothetical. The FDA rejected the drug on August 7 in a complete response letter. Telix’s presentation describes the issues as manufacturing and third-party facility inspections rather than safety or efficacy. Telix inherits the manufacturing fix, and the $700 million in milestones will not start paying until regulators accept it.
Conclusion:
Telix is buying the isotope supply its treatments depend on, plus a late-stage drug, in a deal that puts most of the risk in milestones rather than upfront cash. However, the share issue dilutes existing holders immediately, and the close depends on shareholder and regulatory approval. ITM-11 has also been turned down once already. Two things to watch are the shareholder vote and whether Telix holds full-year guidance of $950 million to $970 million while absorbing a manufacturer.
Market Sentiment:
Telix Pharmaceuticals Limited was held by 4 hedge funds with a combined stake value of about $3 million at the end of Q2 2026 in the Insider Monkey database. This is up from 2 hedge fund holders with a cumulative investment value of around $5.5 million in the previous quarter.
READ NEXT: Oracle (ORCL) Cloud Revenue Jumps 121% and its Backlog Hits $664 Billion. Can it Actually Deliver? and Vicor (VICR) Licenses its Power Patents to Another AI System Maker. Shares Jump 18%
This article is originally published at Insider Monkey.
